{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:49:42Z","timestamp":1761166182442,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.anndiagpath.2023.152262","type":"journal-article","created":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T10:39:31Z","timestamp":1703500771000},"page":"152262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["EphB3 protein is a potential ancillary diagnostic biomarker for thyroid cancers"],"prefix":"10.1016","volume":"69","author":[{"given":"Xinyue","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rusong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxin","family":"Chai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiandong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.anndiagpath.2023.152262_bb0005","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MED.0000000000000359","article-title":"The thyroid cancer epidemic, 2017 perspective","volume":"24","author":"Roman","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.anndiagpath.2023.152262_bb0010","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fendo.2020.00082","article-title":"New therapies for advanced thyroid cancer","volume":"11","author":"Laha","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"10.1016\/j.anndiagpath.2023.152262_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/genes10090723","article-title":"Thyroid cancer in the pediatric population","volume":"10","author":"Paulson","year":"2019","journal-title":"Genes (Basel)"},{"issue":"11","key":"10.1016\/j.anndiagpath.2023.152262_bb0020","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1089\/thy.2021.0119","article-title":"Do ultrasound patterns and clinical parameters inform the probability of thyroid cancer predicted by molecular testing in nodules with indeterminate cytology?","volume":"31","author":"Figge","year":"2021","journal-title":"Thyroid"},{"key":"10.1016\/j.anndiagpath.2023.152262_bb0025","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/912182","article-title":"Impact of molecular testing in the diagnosis of thyroid fine needle aspiration cytology: data from mainland China","volume":"2014","author":"Guo","year":"2014","journal-title":"Dis Markers"},{"issue":"3","key":"10.1016\/j.anndiagpath.2023.152262_bb0030","first-page":"258","article-title":"BRAFV600E mutation testing in fine needle aspirates of thyroid nodules: potential value of real-time PCR","volume":"42","author":"Kwak","year":"2012","journal-title":"Ann Clin Lab Sci"},{"issue":"11","key":"10.1016\/j.anndiagpath.2023.152262_bb0035","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41574-018-0080-7","article-title":"Thyroid surgery for differentiated thyroid cancer - recent advances and future directions","volume":"14","author":"Wang","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"10.1016\/j.anndiagpath.2023.152262_bb0040","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/ng.2007.11","article-title":"EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells","volume":"39","author":"Cortina","year":"2007","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.anndiagpath.2023.152262_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020206","article-title":"The role of the Eph receptor family in tumorigenesis","volume":"13","author":"Anderton","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.anndiagpath.2023.152262_bb0050","doi-asserted-by":"crossref","first-page":"14","DOI":"10.14348\/molcells.2015.2116","article-title":"EphB\/ephrinB signaling in cell adhesion and migration","volume":"38","author":"Park","year":"2015","journal-title":"Mol Cell"},{"issue":"12","key":"10.1016\/j.anndiagpath.2023.152262_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126207","article-title":"Eph receptors and ephrins in retinal diseases","volume":"22","author":"Kaczmarek","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.anndiagpath.2023.152262_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105038","article-title":"Ephrin-Eph signaling usage by a variety of viruses","volume":"159","author":"de Boer","year":"2020","journal-title":"Pharmacol Res"},{"issue":"4","key":"10.1016\/j.anndiagpath.2023.152262_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/biom10040602","article-title":"Expression profile and prognostic significance of EPHB3 in colorectal cancer","volume":"10","author":"Jang","year":"2020","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.anndiagpath.2023.152262_bb0070","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/0008-5472.CAN-10-0717","article-title":"EphB3 is overexpressed in non-small-cell lung cancer and promotes tumor metastasis by enhancing cell survival and migration","volume":"71","author":"Ji","year":"2011","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.anndiagpath.2023.152262_bb0075","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3349\/ymj.2021.62.8.679","article-title":"Low expression of EphB2, EphB3, and EphB4 in bladder cancer: novel potential indicators of muscular invasion","volume":"62","author":"Lee","year":"2021","journal-title":"Yonsei Med J"},{"issue":"1","key":"10.1016\/j.anndiagpath.2023.152262_bb0080","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s12253-018-0562-x","article-title":"Receptor tyrosine kinase EphB3: a prognostic indicator in colorectal carcinoma","volume":"26","author":"Xuan","year":"2020","journal-title":"Pathol Oncol Res"},{"issue":"3","key":"10.1016\/j.anndiagpath.2023.152262_bb0085","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1074\/jbc.M116.750349","article-title":"EphB3 stimulates cell migration and metastasis in a kinase-dependent manner through Vav2-Rho GTPase axis in papillary thyroid cancer","volume":"292","author":"Li","year":"2017","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.anndiagpath.2023.152262_bb0090","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/apm.12646","article-title":"EphB3 protein is associated with histological grade and FIGO stage in ovarian serous carcinomas","volume":"125","author":"Gao","year":"2017","journal-title":"APMIS"},{"issue":"11","key":"10.1016\/j.anndiagpath.2023.152262_bb0095","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1089\/thy.2017.0500","article-title":"The 2017 Bethesda system for reporting thyroid cytopathology","volume":"27","author":"Cibas","year":"2017","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.anndiagpath.2023.152262_bb0100","first-page":"e097","article-title":"The Bethesda system for reporting thyroid cytopathology: validating at Tribhuvan university teaching hospital","volume":"26","author":"Acharya","year":"2021","journal-title":"Int Arch Otorhinolaryngol"},{"key":"10.1016\/j.anndiagpath.2023.152262_bb0105","article-title":"Clinical value of Cyclin D1 and P21 in the differential diagnosis of papillary thyroid carcinoma","volume":"18(1):123","author":"Wang","year":"2023","journal-title":"Diagn Pathol"},{"issue":"3","key":"10.1016\/j.anndiagpath.2023.152262_bb0110","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1507\/endocrj.EJ19-0414","article-title":"Solid variant of papillary thyroid carcinoma: an under-recognized entity","volume":"67","author":"Ohashi","year":"2020","journal-title":"Endocr J"},{"issue":"12","key":"10.1016\/j.anndiagpath.2023.152262_bb0115","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1507\/endocrj.EJ17-0214","article-title":"Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a single-institutional experience in Japan","volume":"64","author":"Hirokawa","year":"2017","journal-title":"Endocr J"},{"issue":"1","key":"10.1016\/j.anndiagpath.2023.152262_bb0120","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s12022-022-09709-1","article-title":"Overview of the 2022 WHO classification of parathyroid tumors","volume":"33","author":"Erickson","year":"2022","journal-title":"Endocr Pathol"},{"issue":"9","key":"10.1016\/j.anndiagpath.2023.152262_bb0125","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1136\/jclinpath-2022-208248","article-title":"Lights on HBME-1: the elusive biomarker in thyroid cancer pathology","volume":"75","author":"Cazzaniga","year":"2022","journal-title":"J Clin Pathol"},{"issue":"12","key":"10.1016\/j.anndiagpath.2023.152262_bb0130","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/14737140.2019.1693270","article-title":"Beyond immunohistochemistry and immunocytochemistry: a current perspective on galectin-3 and thyroid cancer","volume":"19","author":"Li","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"10.1016\/j.anndiagpath.2023.152262_bb0135","first-page":"55","article-title":"Differential diagnostic significance of HBME-1, CK19 and S100 in various thyroid lesions","volume":"39","author":"Palo","year":"2017","journal-title":"Malays J Pathol"},{"key":"10.1016\/j.anndiagpath.2023.152262_bb0140","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1746-1596-7-97","article-title":"Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis","volume":"7","author":"de Matos","year":"2012","journal-title":"Diagn Pathol"},{"issue":"7","key":"10.1016\/j.anndiagpath.2023.152262_bb0145","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.31557\/APJCP.2023.24.7.2305","article-title":"Immunohistochemical expression of HBME-1 and TROP-2 in some follicular-derived thyroid lesions","volume":"24","author":"Abu-Seadah","year":"2023","journal-title":"Asian Pac J Cancer Prev"},{"issue":"4","key":"10.1016\/j.anndiagpath.2023.152262_bb0150","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/sj.bjc.6604194","article-title":"Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV","volume":"98","author":"de Micco","year":"2008","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.anndiagpath.2023.152262_bb0155","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12957-021-02258-7","article-title":"HBME1 and CK19 expression in non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) vs other follicular patterned thyroid lesions","volume":"19","author":"Sadiq","year":"2021","journal-title":"World J Surg Oncol"},{"issue":"2","key":"10.1016\/j.anndiagpath.2023.152262_bb0160","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1507\/endocrj.50.173","article-title":"HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm","volume":"50","author":"Mase","year":"2003","journal-title":"Endocr J"},{"issue":"4","key":"10.1016\/j.anndiagpath.2023.152262_bb0165","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1530\/EJE-19-0223","volume":"181","author":"Bongiovanni","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2023.152262_bb0170","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4183\/aeb.2021.77","article-title":"Malignancy rates of Atypia of Undetermined Significance\/Follicular Lesion of Undetermined Significance (AUS\/FLUS) cases: a tertiary center study","volume":"17","author":"Erdogan-Durmus","year":"2021","journal-title":"Acta Endocrinol (Buchar)"},{"key":"10.1016\/j.anndiagpath.2023.152262_bb0175","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2147\/OTT.S94514","article-title":"Galectin-3 may serve as a potential marker for diagnosis and prognosis in papillary thyroid carcinoma: a meta-analysis","volume":"9","author":"Tang","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"2","key":"10.1016\/j.anndiagpath.2023.152262_bb0180","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/dc.23408","article-title":"Can galectin-3 be a useful marker for conventional papillary thyroid microcarcinoma?","volume":"44","author":"Gweon","year":"2016","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.anndiagpath.2023.152262_bb0185","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13000-015-0428-4","article-title":"Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature","volume":"10","author":"Dun\u0111erovi\u0107","year":"2015","journal-title":"Diagn Pathol"},{"issue":"4","key":"10.1016\/j.anndiagpath.2023.152262_bb0190","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3346\/jkms.2007.22.4.621","article-title":"Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27 (kip1) in the differential diagnosis of thyroid nodules","volume":"22","author":"Park","year":"2007","journal-title":"J Korean Med Sci"},{"issue":"12","key":"10.1016\/j.anndiagpath.2023.152262_bb0195","article-title":"The combined utility of HBME-1 and Galectin-3 immunohistochemistry and BRAF V600E mutations in the diagnosis of papillary thyroid carcinoma","volume":"13","author":"Ramkumar","year":"2021","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.anndiagpath.2023.152262_bb0200","doi-asserted-by":"crossref","first-page":"644","DOI":"10.4103\/jcrt.jcrt_563_21","article-title":"Diagnostic utility of CK19 and galectin-3 in differentiating papillary thyroid carcinoma from nonneoplastic lesions of thyroid","volume":"18","author":"Prasad","year":"2022","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.anndiagpath.2023.152262_bb0205","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1746-1596-6-126","article-title":"Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China","volume":"6","author":"Song","year":"2011","journal-title":"Diagn Pathol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2023.152262_bb0210","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5858\/arpa.2014-0056-RA","article-title":"Application of immunohistochemistry in thyroid pathology","volume":"139","author":"Liu","year":"2015","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.anndiagpath.2023.152262_bb0215","first-page":"111","article-title":"CD56 expression in benign and malignant thyroid lesions","volume":"40","author":"Muthusamy","year":"2018","journal-title":"Malays J Pathol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2023.152262_bb0220","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mce.2009.11.008","article-title":"Genetic markers differentiating follicular thyroid carcinoma from benign lesions","volume":"321","author":"Freitas","year":"2010","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"10.1016\/j.anndiagpath.2023.152262_bb0225","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jasc.2022.09.006","article-title":"Analysis of a pre-2017 follicular variant papillary thyroid carcinoma cohort reclassified as noninvasive follicular thyroid neoplasm with papillary-like features (NIFTP): an 11-year retrospective single institution experience","volume":"12","author":"Beg","year":"2023","journal-title":"J Am Soc Cytopathol"},{"key":"10.1016\/j.anndiagpath.2023.152262_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijscr.2021.106751","article-title":"What you see might not be what you get: analysis of 15 prospective cases of non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)","volume":"91","author":"Al Hassan","year":"2022","journal-title":"Int J Surg Case Rep"},{"key":"10.1016\/j.anndiagpath.2023.152262_bb0235","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.humpath.2018.06.033","article-title":"Exploration of BRAFV600E as a diagnostic adjuvant in the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)","volume":"82","author":"Johnson","year":"2018","journal-title":"Hum Pathol"},{"issue":"27","key":"10.1016\/j.anndiagpath.2023.152262_bb0240","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2018.33.e75","article-title":"Prevalence of BRAF (V600E) mutation in follicular variant of papillary thyroid carcinoma and Non-Invasive Follicular Tumor with Papillary-Like Nuclear Features (NIFTP) in a BRAF (V600E) prevalent area","volume":"33","author":"Kim","year":"2018","journal-title":"J Korean Med Sci"},{"issue":"2","key":"10.1016\/j.anndiagpath.2023.152262_bb0245","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12022-022-09721-5","article-title":"Systematic review and Meta-analysis to identify the Immunocytochemical markers effective in delineating benign from malignant thyroid lesions in FNAC samples","volume":"33","author":"Mohan","year":"2022","journal-title":"Endocr Pathol"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913423001600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913423001600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:36:07Z","timestamp":1761078967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913423001600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":49,"alternative-id":["S1092913423001600"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2023.152262","relation":{},"ISSN":["1092-9134"],"issn-type":[{"type":"print","value":"1092-9134"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EphB3 protein is a potential ancillary diagnostic biomarker for thyroid cancers","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2023.152262","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152262"}}